JP2025515091A - 眼疾患を治療するための補体因子i投与レジメン - Google Patents

眼疾患を治療するための補体因子i投与レジメン Download PDF

Info

Publication number
JP2025515091A
JP2025515091A JP2024564919A JP2024564919A JP2025515091A JP 2025515091 A JP2025515091 A JP 2025515091A JP 2024564919 A JP2024564919 A JP 2024564919A JP 2024564919 A JP2024564919 A JP 2024564919A JP 2025515091 A JP2025515091 A JP 2025515091A
Authority
JP
Japan
Prior art keywords
eye
cfi
weeks
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515091A5 (cg-RX-API-DMAC7.html
Inventor
イー ブラウズ,グラント
モアン,ナターシャ ル
ヌードセン,トム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2025515091A publication Critical patent/JP2025515091A/ja
Publication of JP2025515091A5 publication Critical patent/JP2025515091A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
JP2024564919A 2022-05-04 2023-05-04 眼疾患を治療するための補体因子i投与レジメン Pending JP2025515091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338392P 2022-05-04 2022-05-04
US63/338,392 2022-05-04
PCT/US2023/066620 WO2023215840A1 (en) 2022-05-04 2023-05-04 Complement factor i dosing regimens for treating ocular diseases

Publications (2)

Publication Number Publication Date
JP2025515091A true JP2025515091A (ja) 2025-05-13
JP2025515091A5 JP2025515091A5 (cg-RX-API-DMAC7.html) 2026-05-14

Family

ID=86760162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564919A Pending JP2025515091A (ja) 2022-05-04 2023-05-04 眼疾患を治療するための補体因子i投与レジメン

Country Status (10)

Country Link
US (1) US20250177482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515091A (cg-RX-API-DMAC7.html)
KR (1) KR20250008764A (cg-RX-API-DMAC7.html)
CN (1) CN119698286A (cg-RX-API-DMAC7.html)
AU (1) AU2023265150A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251504A1 (cg-RX-API-DMAC7.html)
IL (1) IL316772A (cg-RX-API-DMAC7.html)
TW (1) TW202400627A (cg-RX-API-DMAC7.html)
WO (1) WO2023215840A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021257480A2 (en) * 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
KR20250008764A (ko) 2025-01-15
AU2023265150A1 (en) 2024-11-14
CA3251504A1 (en) 2023-11-09
CN119698286A (zh) 2025-03-25
WO2023215840A1 (en) 2023-11-09
EP4518881A1 (en) 2025-03-12
IL316772A (en) 2025-01-01
US20250177482A1 (en) 2025-06-05
TW202400627A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
Duh et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth
CN100528235C (zh) 红细胞生成素共轭物
CN100422332C (zh) 表达以及分泌制管张素和endostatin的免疫融合物
AU2008261591B2 (en) ACE2 polypeptide
US12116606B2 (en) Complement factor I-related compositions and methods
CN103797115A (zh) 具有快速加工性能的经过修饰的酸性α葡糖苷酶
JPH0720431B2 (ja) ミュレル管抑制物質の活性を示すポリペプチドをコードするdna,組換dnaおよび形質転換宿主
KR20220156934A (ko) 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
CN103159860B (zh) 重组组织型纤溶酶原激活剂及其制备方法与用途
CN112384236A (zh) 用于治疗微血管血栓形成的靶向溶栓
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
CN1051934A (zh) 在真核细胞中表达神经生长因子的基因构建物的制备方法
JP2022548367A (ja) 眼科障害の処置または防止における使用のための薬剤
US7078485B2 (en) N-terminal modified recombinant human endostatin and its production
CN118804759A (zh) 补体因子i相关的组合物和方法
RU2344172C2 (ru) Мутеины плацентарного фактора роста 1 типа, способ их получения и применение
US20250177482A1 (en) Complement factor i dosing regimens for treating ocular diseases
CN101914161A (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
CN101155916A (zh) 作为血栓溶解剂的靶向性纤溶酶原激活物融合蛋白
JP2637392B2 (ja) 遺伝子操作による生物活性β−NGFの生産方法
EP0444638A2 (en) Process for the expression of human nerve growth factor in arthropoda frugiperda cells by infection with recombinant baculovirus
US20220168434A1 (en) Application of transthyretin in entering eye and preparing drop
US6329500B1 (en) Transforming growth factor-β binding site
CN116635528A (zh) 补体因子i相关组合物和方法
EA052996B1 (ru) Усеченные формы iga-протеазы, слитые белки, содержащие усеченную форму iga-протеазы, и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260501